Compare Vaxcyte Inc. Common Stock (PCVX) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs iShares Silver Trust — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.63B), while iShares Silver Trust trades at $51.11 (market cap $28.90B). The key difference: iShares Silver Trust is far larger — about 2.7× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and iShares Silver Trust for 90 Days on average.
| PCVX | SLV | |
|---|---|---|
Market Cap | $10.63B | $28.90B |
Volume | 1,525,205 | 36,248,796 |
Sector | Health | — |
52-Week High | $73.82 | $105.57 |
52-Week Low | $40.32 | $42.40 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $9.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLV (iShares Silver Trust) trades at $53.49, down 1.58% amid bearish technical signals with 17 sell indicators versus 1 buy. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024, supported by $13.41B in total assets against negligible liabilities. Recent news highlights silver's volatility tied to Fed policy and Treasury yields, with prices pressured by hawkish rate expectations.
Outlook remains cautious as technical weakness and macroeconomic headwinds dominate. Silver's dual role as monetary and industrial metal exposes SLV to Fed policy shifts and dollar strength, though long-term demand catalysts like central bank buying offer potential upside. Risks include sustained rate hikes and industrial demand fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
